Your next three webinars

What changed

About the same number of women reach your sign-up page each month. Since March 2026 it has been 1,221 to 1,541 visits a month. What changed is how many of them sign up.

In June and July 2025, 19.5 and 17.6 percent of visitors signed up. In July, September and October 2026, about 6 percent did. So the same visits now bring far fewer registrations.

Causes we ruled out

We checked each likely cause against your Facebook and Instagram ads, your website visitor numbers and your booking records. None of these explains the drop. We compared the slow months, June to October 2026, with the strong months, December 2025 to March 2026.

• Ad money. Your ads spent $1,925 to $2,404 a month in the slow months, and $1,810 to $2,213 in the strong months. The slow months did not get less money.
• Ad clicks. The slow months averaged 1,224 ad clicks a month. The strong months averaged 1,305.
• Weaker ads. The ad click rate (the share of people who saw the ad and clicked) went up in the slow months, to 1.47 to 1.83 percent. In the strong months it was 1.17 to 1.71 percent.
• Seeing the ads too often. Each person saw the ads 1.65 to 1.87 times in the slow months, and 1.77 to 2.24 times in the strong months.
• Where the ads showed. Ads shown inside other apps brought some weak clicks in June and July 2026. September and October had almost none of those, and still only 5.7 and 6.0 percent signed up.
• A worn out list. From February to October 2026, 70 to 84 percent of each webinar's registrations were new to your records.

So the drop happens on the sign-up page, after the click. The topic and title are the strongest explanation left. That part is not proven yet. The next section shows why we think so.

What worked

Two views of the same 21 webinars. The first follows a woman from the ad to the sign-up page. The second follows her from signing up to your team.

Sign ups by webinar

From your Facebook and Instagram ads and your website visitor numbers. Ad cost per sign up uses your ads' own count of sign ups, so it differs a little from Registered.

Look at the ads, not only the totals. In your ad results, ads with one specific hook brought sign ups for about $8 to $22 each, and most of them for about $12 or less. The hook was pain after surgery (July, August, November and December 2025) or a stack of symptoms like fatigue, bloating and brain fog (January and February 2026). Since April 2026 the ads asked whether period pain is normal. At the low point, in July and September 2026, they cost about $31 to $41 a sign up.

Calls by webinar

From your booking records. A success call is the follow up call a registrant books with your team. Appointments and Closed count only records made after the woman registered.

September 2026 and October 2026 are left out of the rows above. September booked far fewer calls than any other month, for a reason we are still checking, so we do not read it as a topic result. October is still counting. "Closed" is a stage in your booking records. Your team has not told us what it means yet, so we write "reached the Closed stage in your records" and ask you in question 11.

The pattern

The nine webinars from July 2025 to March 2026 each named one condition or experience, like adenomyosis, staging or pain after surgery. They signed up 13.5 percent of visitors on average. The seven webinars since April, most of them asking whether period pain is normal, signed up 8.3 percent. That is true even though their ads got more clicks: a 1.61 percent ad click rate, against 1.21 percent.

Your booking records point the same way. Webinars that answer one question you hear in the exam room booked the most success calls per sign up: Staging at 25 percent, Dismissed at 29 percent. Broad symptom lists booked the fewest, 10 to 12 percent.

The number of patients per webinar is small, so one or two patients can move a webinar up or down this list. Read it as a direction, not proof. November's two sign-up pages are the test.

Your three webinars

Each one names a single problem a woman already knows she has. All three dates are proposed, to confirm with you. Every estimate is at today's ad budget.

In each estimate, low means the topic is not what fixes the sign-up rate. The plan number counts on your yes to invites to past registrants (question 7) and invites on your blog (question 8).

November

Who it is for

Women who had a laparoscopy, ablation or hysterectomy and still have pain.

Why this topic

• Your surgery webinars drew 229 (August 2025), 129 (November 2025) and 138 (March 2026). Each signed up 11.6 to 12.5 percent of visitors. From your booking records and your website visitor numbers.
• In 2025, ads with a pain after surgery hook brought sign ups for about $12 to $22 each. At the low point this year, the "is my period normal" ads cost about $31 to $41. From your ad results.
• Your most clicked article is your surgery recovery article: 3,089 clicks from Google in 90 days. From your Google search data.
• Surgery topics bring past registrants back. In November 2025, 30 percent of registrants had signed up for an earlier webinar, the highest share of all 21. From your booking records.
• August 2025 reached 5.2 appointments or Closed stage records per 100 registrations, fifth of 21. From your booking records.

What to expect

Estimate, in registrations and success calls. Every number is approximate.

How we fill seats

• Open sign ups by October 28. About a third of your sign ups come 7 or more days before the webinar.
• The ad hook: "Surgery was supposed to fix it. Here is why some pain stays after surgery, and what to ask next." It is the hook from your August 2025 ads, rewritten. You see the wording before it runs.
• With your yes, your two sign-up pages carry two different November titles for the first 7 days, and we keep the one that signs up more.
• With your yes, a text and email invite goes to past registrants who have not booked, 10 days out and 2 days out.
• With your yes, an invite goes on your 10 surgery articles, starting with your surgery recovery article.
• From your quarterly plan, these pages go up first and point to the webinar: "Still in Pain After Endometriosis Surgery? Second Opinions", "Excision or Ablation" and "Laparoscopy for Endometriosis".
• These articles from the plan point to it too: "Life After Endometriosis Surgery: The First Year", "Why Is My Endometriosis Pain Getting Worse?", "Questions to Ask After Endometriosis Surgery", "Reading Your Surgery Report Before a Second Opinion" and "Bleeding After Endometriosis Surgery".
• Two Google profile posts, 10 days and 3 days out.

December

Who it is for

Women with heavy, painful periods who want to know whether adenomyosis is part of the answer, including women weighing a hysterectomy.

Why this topic

• Adenomyosis drew 249 in July 2025, with 17.6 percent of visitors signing up, and 170 in December 2025, at 15.3 percent. Both are among your strongest. From your booking records and your website visitor numbers.
• "adenomyosis" gets about 201,000 searches a month nationwide, the most of any search we checked for these webinars. From our keyword tools.
• It brings past registrants back: 41 in July 2025 and 32 in December 2025. From your booking records.
• It reached 4.4 (July 2025) and 4.1 (December 2025) appointments or Closed stage records per 100 registrations. Both are in the top 10 of 21. From your booking records.

One risk. This is the third webinar on adenomyosis, and the second drew fewer than the first, 170 against 249. So the titles take new angles: both conditions together, and the question of hysterectomy.

What to expect

Estimate, in registrations and success calls. Every number is approximate.

How we fill seats

• The ad hook names one condition worth asking about: heavy, painful periods with a scan that looked normal. You see the wording before it runs.
• With your yes, a text and email invite goes to past registrants who have not booked, 10 days out and 2 days out, with a short note for women who came to an earlier adenomyosis webinar.
• With your yes, an invite goes on your 5 articles about adenomyosis, heavy bleeding and cycle changes.
• From your quarterly plan, these pages go up first and point to the webinar: "Adenomyosis: Diagnosis and Treatment Options" (live in November) and "Hysterectomy and Endometriosis: What to Know Before You Decide".
• These articles from the plan point to it too: "Adenomyosis: When to Get a Second Opinion" and "Endometriosis After Hysterectomy and Menopause".
• Two Google profile posts before the webinar.

January

This is the newest and least tested of the three. You have never run a webinar like it. The two closest past topics, both about treatment choices, drew 59 (April 2025) and 100 (May 2025).

ENDO-205 is an investigational drug. It is not FDA approved. It would be about a third of the hour. The rest is what works today. If you say no to this topic, the fallback is digestive symptoms and bloating, the topic that drew 257 in February 2026.

Who it is for

Women who saw news or posts about a new endometriosis drug and want a straight answer from a specialist. Also anyone weighing medicine against surgery.

Why this topic

• "endo 205", an investigational drug that is not FDA approved, gets about 1,600 searches a month nationwide. No medical practice shows in the top results. From our keyword tools.
• The bigger question behind it is searched too: "can endometriosis be cured" about 1,600 a month, and "how to cure endometriosis" about 1,300. From our keyword tools.
• Women are already talking about it on Reddit, Instagram and YouTube, which show in the top results. From our keyword tools.
• January is not a weak month. Your January 2026 webinar drew 163, and 16.6 percent of visitors signed up. From your booking records and your website visitor numbers.

What to expect

Estimate, in registrations and success calls. Every number is approximate. No past webinar matches this one closely, so success calls use a lower call rate.

How we fill seats

• The ad teaches and makes no claim about the reader: "A new endometriosis drug made headlines. It is investigational and not FDA approved. A Dallas excision surgeon explains what it is, what is still unknown, and what works today." You see the wording before it runs.
• With your yes, one sign-up page asks the cure question and the other names ENDO-205, an investigational drug that is not FDA approved, for the first 7 days. We keep the one that signs up more.
• With your yes, a text and email invite goes to past registrants who have not booked, 10 days out and 2 days out.
• With your yes, an invite goes on your 7 articles about treatment choices and natural remedies.
• From your quarterly plan, these go up first and point to the webinar: the article "Is Endometriosis Curable? An Honest Answer About What Excision Removes", and the "Endometriosis Treatment Options" and "Excision Surgery Results: What Affects Them" pages.

About ENDO-205

Every fact below links to its public source. Each link opens in a new tab.

What it is

ENDO-205 is an investigational drug for endometriosis from one drug company. It is not FDA approved.

What is known

• On March 23, 2026, the FDA cleared the company's application to begin testing it in people, says the company press release. That allows a first study, and nothing more.
• The same press release says the planned first study is in healthy premenopausal women. A news explainer says that study mainly checks safety and dosing.

What is not known

• Whether it treats endometriosis. As one news explainer puts it, later studies would have to show that.
• When a study starts. ClinicalTrials.gov, the public list of studies, showed no study of it on October 16, 2026.

Why women ask

"endo 205" gets about 1,600 searches a month nationwide, from our keyword tools. The top results are the drug company, government research pages, a medical news site, Reddit, Instagram and YouTube. None is a medical practice. Google's "People also ask" box for it includes "Is endo 205 peptide available for sale?" It is investigational and not FDA approved, so a clear answer from a specialist protects patients.

How it helps patients

1. Searchers already ask whether it is for sale, in Google's "People also ask" box. You can say plainly that it is not an approved treatment and cannot be bought as one.
2. Waiting has a cost. The first study checks safety in healthy volunteers, not whether it treats endometriosis. Nobody should put off care for a drug whose first study is not listed yet.
3. No medical practice shows in the top results yet. Today the answers come from the drug company, government research pages, a medical news site and social media.

How we label it

• Every ad, page, invite and post calls it investigational and not FDA approved, every time it is named.
• Nothing says or hints that it is for sale, or that a woman can join a study as treatment.
• No ad tells the reader she has endometriosis. No patient stories about it.
• Any cure wording stays a question, never a claim. You approve the wording before anything runs.

How we get there

The math

The estimates use 1,250 sign-up page visits a month. That is a little under the 1,307 average of your last six webinars.

Those four months were June, July and December 2025 and January 2026. So the goal is a return to your own level, not a new record. In October 2026, 6.0 percent signed up. At 1,250 visits that is about 75 registrations from the ads.

Four levers

Your blog is the lever nobody has used yet. Your website gets about 14,000 clicks a month from Google, 42,101 in the last 90 days across 1,647 pages. In every month we can see, your website sent zero visitors to the webinar sign-up page.

Without your yes on questions 7 and 8, the plan rests on the ads and the sign-up page alone: about 138 in November, 150 in December and 113 in January.

What we measure

For each webinar, every month, we report these next to the estimates on this page.

• Registrations.
• The share of sign-up page visitors who signed up.
• Success calls booked.
• Appointments booked after registering.
• Records that reached the Closed stage after registering.
• The 7 day title test: on day 7 we compare the two sign-up pages and keep the title that signed up more.

Questions for you

A short answer to each is enough.

1. Will you do the January webinar on new treatments, with ENDO-205 as one part, called investigational and not FDA approved every time it is named? If yes, which title?
2. Would you speak to other new treatments in research too, or ENDO-205 only?
3. Do these dates work: November 11 (Veterans Day) or November 18, December 9 and January 13, all at 12 PM Central?
4. November: may we say you review earlier operative reports and do repeat excision for women still in pain after surgery?
5. December: what do you offer for adenomyosis besides hysterectomy, and what should we not say?
6. Is there a topic you want to avoid, or one patients keep asking you about?
7. May we text and email the webinar invite to the 1,571 past registrants who have not booked?
8. May we add a webinar invite to your blog articles?
9. May your two sign-up pages carry two different titles in November, to find the stronger one?
10. Who on your side signs off on ad and page wording?
11. What does "Closed" mean to your team?